Evaluation of antibiotic cycling and prophylaxis for neutropenic fever within a blood and marrow transplantation unit  by Craig, M. et al.
multiorgan failure. No unexpected OT was noted. Fifty-four of the
72 patients (75%) received VOR until day 100 without interrup-
tion. The reasons for VOR discontinuation were increased LFTs
in 11 patients, prolonged QTc in 2, and suspected resistant IFI in
2. The LFT increases were transient. The median total bilirubin,
alkaline phosphatase, and AST values were 1.3 mg/dL, 134 U/L,
and 34 U/L, respectively. Eight patients developed total biliru-
bin  6 mg/dL, and 3 had VOD. Four patients restarted VOR
following improved LFTs. No signiﬁcant cardiac toxicity was
noted, despite a QTc of  500 msec in 10 patients. The mean
increase in QTc after starting VOR was 34 msec (n  36). The
mean peak creatinine level was 1.5 mg/dL. Four patients required
HD. Engraftment did not appear to be adversely affected, with
means of 14 days to ANC  0.5/L and of 20 days to platelets 
50 103/L. VOR did uniformly increase serum tacrolimus levels,
necessitating a 60% reduction in tacrolimus dosing. Conclusions:
VOR appears safe and effective as prophylaxis for AT. Tacrolimus
levels must be closely monitored. A randomized trial comparing
VOR to FLU in AT is warranted.
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ANTIFUNGAL PROPHYLAXIS WITH VORICONAZOLE IN ALLOGENEIC
HEMATOPOIETIC STEM CELL TRANSPLANTATION RECIPIENTS
Magalhaes-Silverman, M., Carter, T., Hohl, R., Shamsuddin, H.,
Gingrich, R. University of Iowa, Iowa City, IA.
Background: Invasive fungal infection (IFI) remains a major
cause of morbidity and mortality in recipients of allogeneic hema-
topoietic stem cell transplantation (HSCT). In many transplanta-
tion centers, Aspergillus has been the leading cause of death from
fungal infections. Voriconazole is a triazole with broad-spectrum
antifungal activity against several molds, including Aspergillus. In
our institution, voriconazole was instituted as antifungal prophy-
laxis in July 2002. Before the institution of voriconazole, invasive
aspergillosis (IA) was the most commom fungal infection in our
allogeneic HSCT population, with 3 years of surveillance revealing
a cumulative incidence of proven or probable IA of 12%. Meth-
ods: From July 2002 to March 2004, 40 adult patients undergoing
allogeneic HSCT received oral voriconazole 200 mg every 12
hours from initiation of the preparative regimen until at least
posttransplantation day 100. After day 100, voriconazole was
continued in patients requiring corticosteroids for therapy of
GVHD. Intravenous voriconazole was allowed in patients not able
to take oral medications. All these patients were at high risk for
Aspergillus infection. Diagnoses included myeloid malignancies in
23 patients, lymphoid malignancies in 16, and renal cell cancer in
1. Median patient age was 47 years. Some 75% of the patients had
advanced disease, and 50% received an unrelated donor transplant.
T-cell depletion was achieved using either OKT3 or Campath-1H
in 75% of the patients. GVHD requiring high-dose corticosteroids
occurred in 50% of the patients. Results: Voriconazole had to be
discontinued in 1 patient due to hallucinations; this patient devel-
oped and died from IA. Three cases of candidemia caused by
Candida glabrata were diagnosed (all 3 cases caused by voricon-
azole-resistant organisms). Disseminated zygomycosis was identi-
ﬁed and caused the death of 2 patients at days 25 and 196 after
transplantation. Conclusions: In this high-risk patient population,
only 1 case of IA was diagnosed. This compares favorably with
historical results: However, 2 cases of disseminated zygomycosis
were diagnosed. Our experience raises concern regarding the
changing epidemiology of IFI as practices using prophylactic an-
tifungal agents evolve.
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PHARMACOKINETICS OF HIGH-DOSE WEEKLY AMBISOME (LIPOSO-
MAL AMPHOTERICIN B) ANTIFUNGAL PROPHYLAXIS IN PEDIATRIC
BONE MARROW TRANSPLANTATION (BMT) PATIENTS
Mehta, P.A., Vinks, A.A., Filipovich, A.H., Vaughn, G.A.,
Fearing, D.N., Sper, C., Davies, S.M. Cincinnati Children’s Hospital
Medical Center, Cincinnati, OH.
Background: Disseminated fungal infection is a major cause of
morbidity and mortality in children undergoing BMT. Prophylac-
tic oral triazoles are limited by poor absorption, interindividual
variation in metabolism, and hepatic toxicity. Ambisome is shown
to produce higher plasma and tissue concentrations and has a
better safety proﬁle than the parent drug amphotericin B; however,
it requires frequent intravenous administration. Both animal (mu-
rine models for Candida/Histoplasma) and human (adult) data show
measurable plasma and tissue levels at 7 days after a single dose
(2–20 mg/kg) of Ambisome. We hypothesized that weekly high-
dose Ambisome will provide adequate fungal prophylaxis for im-
munocompromised children. This dosing schedule will improve
compliance and broaden the applicability of Ambisome to a larger
patient population.Methods: A total of 14 children (M/F ratio 2:1,
age 10 years [mean age, 3.3 years]) with various hematologic
conditions, metabolic disorders, and immunodeﬁciency syndromes
at risk for invasive fungal infection received once-a-week intrave-
nous Ambisome prophylaxis at the dose of 10 mg/kg given over 2
hours. Blood samples were drawn for phrmacokinetic (PK) mea-
surements around the ﬁrst and the fourth weekly doses. PK analysis
of single-dose and steady-state data was conducted using standard
noncompartmental methods. Individual plasma trough concentra-
tions were determined by visual inspection of the plasma concen-
tration time proﬁles. The area under the plasma concentration
versus time curve (AUC0-) was determined using the log-linear
trapezoidal rule. Total body clearance (CL), volume of distribution
(Vz), and terminal half-life (T1⁄2) were calculated using standard
equations. Results: Ambisome was well tolerated at this dosage.
Half-life measured in this pediatric population appears to be
shorter than reported in adults (45 hours vs 152 hours). Volume of
distribution and clearance were higher compared to adult reports
and correlated positively with body weight (r2  0.62 for Vz; r2 
0.28 for Cl). Plasma levels at 7 days (Cmin) were not signiﬁcantly
different after the ﬁrst and fourth doses, suggesting no accumula-
tion over the course of therapy. Conclusions: Our data show
measurable plasma levels present 7 days after the dose. Adult
studies show tissue concentrations  10-fold higher than plasma
concentrations, suggesting that once-weekly dosing, as described
in this study, likely provides useful protection against fungal infec-
tion.




Dose (n  12)
After Multiple
Doses (n  9)
T1⁄2 (h) 45.44 (15.43) 58.94 (26.42)
Day 7 plasma trough
(Cmin; mg/L) 0.23 (0.14) 0.51 (0.46)
AUC0-INF (hr  mg/L) 157.51 (71.71) 230.08 (132.67)
Vz (L/kg) 4.29 (1.01) 4.97 (2.96)
Cl (L/hr/kg) 0.0742 (0.0341) 0.0669 (0.0442)
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EVALUATION OF ANTIBIOTIC CYCLING AND PROPHYLAXIS FOR NEU-
TROPENIC FEVER WITHIN A BLOOD AND MARROW TRANSPLANTA-
TION UNIT
Craig, M.1, Cumpston, A.1, Shields, R.2, Devetten, M.3, Sarwari, A.1,
Ericson, S.1 1West Virginia University, Morgantown, WV; 2St. Jo-
seph’s/ Candler Health System, Savannah, GA; 3University of Ne-
braska, Omaha, NE.
Background: Bacterial resistance to antibiotics is an increasing
problem and associated with signiﬁcant morbidity and mortality.
Patients undergoing HSC transplantation and treatment for he-
matologic malignancy are at high risk of infection. We evaluated
whether rotating the empiric antibiotics for patients who develop
neutropenic fever in this setting resulted in decreased emergence
of resistant organisms and decreased vancomycin use. Methods:
Within the BMTU, all patients with neutropenic fever were em-
pirically treated with piperacillin plus gentamicin (intermittent
dosing) from January 1999 to February 2002. From March 2002
through June 2004, 3 antibiotic regimens were cycled every 8
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months in the empiric treatment of neutropenic fever: imipenem
monotherapy, cefepime plus tobramycin (extended-interval dos-
ing), and piperacillin/tazobactam plus tobramycin (extended-inter-
val dosing). Levoﬂoxacin was initiated as prophylaxis in March
2002 if the duration of neutropenia was expected to be  10 days.
For the time periods before (January 1999 to December 2001) and
after (January 2002 to June 2004) the initiation of antibiotic cycling
and levoﬂoxacin prophylaxis, we retrospectively compared the rates
of bacteremia (excluding coagulase-negative staphylococcus) and
antimicrobial use. Results: The rate of gram-positive bacteremia
was similar in the 2 periods (4.6 vs 4.8 episodes/1000 patient days;
P .87). However, there was an emergence of methicillin-resistant
Staphylococcus aureus, vancomycin-resistant Enterococcus faecium, and
levoﬂoxacin-resistant Streptococcus species during the period of anti-
biotic rotation and prophylaxis. Gram-negative bacteremia rates
decreased signiﬁcantly (4.8 vs 1.8 episodes/1000 patient days; P 
.003), and Klebsiella species disappeared from culture isolates. After
the initiation of antibiotic cycling, the rates of Pseudomonas isolates
decreased (1.7 vs 0.7 episodes/1000 patient days; P  .09), and
isolated strains were less resistant to ceftazidime and piperacillin.
Vancomycin use decreased during the period of antibiotic cycling
and prophylaxis (397 vs 289 deﬁned daily dose/1000 patient days;
P  .001). Conclusions: The introduction of antibiotic cycling
and prophylaxis in our BMT unit was associated with a signiﬁcant
decrease in gram-negative bacteremia rates. Although there was no
evidence of emerging resistance among the gram-negative isolates,
there was an increased rate of MRSA and VRE bacteremia.
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SINGLE CENTER EXPERIENCE WITH COLLECTION AND ADMINISTRA-
TION OF G-CSF–MOBILIZED, IRRADIATED GRANULOCYTE TRANSFU-
SIONS FROM DIRECTED DONORS TO SUPPORT PATIENTS AT HIGH
RISK FOR INFECTIONS UNDERGOING UNRELATED DONOR BLOOD AND
MARROW TRANSPLANTATION
Allison, J., Stephens, C., Waters-Pick, B., Bradshaw, T., Whitlock, P.,
Kurtzberg, J. Duke University Medical Center, Durham, NC.
Over the past 7.5 years, we supported patients at increased risk
for infection for 4–10 weeks posttransplantation with G-CSF
primed, irradiated granulocyte transfusions (grans) harvested from
a healthy family member. After clearance and placement of a
central venous catheter, donors were injected with G-CSF (10
g/kg) 12–15 hours before donation, twice weekly, 3 days apart.
Grans were collected on a Baxter CS3000 blood separator, irra-
diated, and divided into 3 equal aliquots to be administered on the
day of collection and the next 2 days. RBC and plasma were
depleted as needed to prevent reactions due to ABO incompatibil-
ity between the patient, their transplantation donor, and the gran-
ulocyte donor. Grans were stored at 4°C on a blood rotator until
warming to room temperature before infusion. Each collection was
tested for cell count, viability, bacterial and fungal cultures. After
premedication with antihistamines and steroids, the grans were
infused into the patient over 2 hours daily for 6–7 days per week.
Patients did not receive more than 5  108 cells/kg during a single
infusion. Donors were supported with iron, vitamin K, and cal-
cium. A total of 82 patients (32 with fungal infections, 26 under-
going second transplant, 22 with other infections, and 2 with
surgical wounds) received 2800 granulocyte transfusions from 91
donors harvested in 939 separate donation procedures. The aver-
age number of donations per donor was 10 over 5 weeks. The
average WBC in donors before collection was 42.17  106/L
(range, 3.49–87.9). The median number of grans collected at each
procedure was 5.71  1010 total cells (range, 0.025–21.7), with a
viability of  98%. Some 6% of the collections were discarded
before infusion due to bacterial contamination (3%) or clotting
(3%). Donor complications included line infection in 14% of
donors requiring CVL removal in 5%, pruritis in 2.5%, and hy-
poproteinemia in 1%. The mean drop in donor hemoglobin be-
tween the ﬁrst and last procedure was 2 g. There were no serious
complications in gran recipients. Less than 10% of patients with
active infections experienced progression or recurrence of infec-
tion on granulocyte support. We conclude that patients with in-
vasive fungal disease, prolonged neutropenia, and surgical wounds
can be maintained infection-free during marrow aplasia after allo-
geneic stem cell transplantation with regular transfusions of irra-
diated granulocytes. Risks to donors are minimal despite repeated
donations over 1–2 months.
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SAFETY OF BISPHOSPHONATE USE IN HEMATOPOIETIC PROGENITOR
CELL TRANSPLANTATION IN MULTIPLE MYELOMA PATIENTS
Mazj, S., Ng, N., Lichtman, S.M., John, V., Devoe, C., Bayer, R.-L.
North Shore University Hospital, Manhasset, NY.
Background: The clinical course of multiple myeloma is often
associated with signiﬁcant bone disease. Bisphosphonates have
been shown to reduce the number of skeletal events. Treatment is
continued even after hematopoietic progenitor cell transplant.
Studies have shown renal toxicity associated with different bisphos-
phonates.Methods:We retrospectively reviewed the records of all
multiple myeloma patients who underwent hematopoietic progen-
itor cell transplantation and received bisphosphonates during the
period January 2001 to June 2004 at our institution. A total of 22
patients were analyzed. The types of bisphosphonates used were
zolendronate and pamidronate. Patients were categorized as to the
type of bisphosphonate used and age. Renal dysfunction was de-
ﬁned as an increase in serum creatinine of  0.5 mg/dL over
baseline. Results: Five of the 22 patients (22.7%) developed renal
dysfunction. The table shows the distribution of patients, type of
bisphosphonate, and the distribution of patients with renal toxicity.
Among the 5 patients who developed renal impairment, 4 patients
(80%) completely recovered their renal function and continued to
use bisphosphonates. Conclusions: The analysis shows that
bisphosphonates can be safeley used in multiple myeloma patients
who have undergone hematopoietic progenitor cell transplant. If
renal dysfunction develops during treatment, then the bisphospho-
nate can be discontinued temporarily. Renal function is likely to
recover, and the bisphosphonate can be safely reimplemented.
Table 1. All Patients Who Received Bisphosphonates by Type and Age
(1/2001–6/2004)
Age Group Zometa Aredia Zometa and Aredia Total
30–39 0 0 0 0
40–49 4 0 2 6
50–59 4 1 1 6
60–69 5 3 1 9
70–79 0 0 1 1
80 0 0 0 0
Total 0 0 0 22
Renal Impairment by Age and Type of Bisphosphonate in
Transplanted Multiple Myeloma Patients
30–39 0 0 0 0
40–49 1 0 1 2
50–59 0 0 0 0
60–69 0 2 0 2
70–79 0 0 1 1
80 0 0 0 0
Total 1 2 2 5
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VALGANCICLOVIR FOR THE PROPHYLAXIS OF EARLY CYTOMEGALOVIRUS
(CMV) INFECTION AFTER ALLOGENEIC STEM CELL TRANSPLANTATION
Bachier, C.1, Shaughnessy, P.1, Wall, D.1, Grimley, M.1, Carrum, G.2,
Freytes, C.3, Callander, N.3, Walsh, T.3, LeMaistre, C.F.1 1Texas
Transplant Institute, San Antonio, TX; 2Center for Cellular and Gene
Therapy, Houston, TX; 3University of Texas Health Science Center, San
Antonio, TX.
The use of highly immunosuppressive therapies prior to and after
transplantation and the use of matched unrelated (MUD) and
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